Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma
Introduction: The past decade has seen the development and widespread use of tyrosine
kinase inhibitors (TKIs) targeting a mutated EGFR (mEGFR) for the treatment of metastatic …
kinase inhibitors (TKIs) targeting a mutated EGFR (mEGFR) for the treatment of metastatic …
Mapping bone marrow response in the vertebral column by positron emission tomography following radiotherapy and erlotinib therapy of lung cancer
A Abravan, HA Eide, AM Løndalen, Å Helland… - Molecular Imaging and …, 2019 - Springer
Purpose To map functional bone marrow (BM) by 2-deoxy-2-[18 F] fluoro-d-glucose ([18 F]
FDG) positron emission tomography (PET) in the vertebral column of lung cancer patients …
FDG) positron emission tomography (PET) in the vertebral column of lung cancer patients …
Rapid evaluation of tyrosine kinase activity of membrane-integrated human epidermal growth factor receptor using the yeast Gγ recruitment system
Epidermal growth factor receptor (EGFR) is a member of the receptor tyrosine kinase family
and plays key roles in the regulation of fundamental cellular processes, including cell …
and plays key roles in the regulation of fundamental cellular processes, including cell …
Development and validation of a UPLC–MS/MS assay for the quantification of simotinib in human plasma
N Li, X Han, P Du, Y Song, X Hu, S Yang… - Analytical and bioanalytical …, 2014 - Springer
Simotinib is a novel oral small-molecule tyrosine kinase inhibitor that has demonstrated
equal or superior antineoplastic activities to erlotinib in preclinical studies. In support of a …
equal or superior antineoplastic activities to erlotinib in preclinical studies. In support of a …
Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies
Cancer is one of the dominant causes of death worldwide while lifelong prognosis is still
inauspicious. The maturation of the cancer is seen as a process of transformation of a …
inauspicious. The maturation of the cancer is seen as a process of transformation of a …
Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!
S Stintzing, HJ Lenz - Expert opinion on pharmacotherapy, 2013 - Taylor & Francis
Introduction: Increased understanding in intracellular signaling pathways leading to
carcinogenesis, proliferation, migration, invasion, angiogenesis, and anti-apoptosis of …
carcinogenesis, proliferation, migration, invasion, angiogenesis, and anti-apoptosis of …
[HTML][HTML] International biobanking for lung cancer and COPD as the future resource for clinical protein research
Characterized tissue with pathological grading and blood samples as well as other biofluids
forms the basis for all biobanks as a resource in modern life science. Biobanks are accessed …
forms the basis for all biobanks as a resource in modern life science. Biobanks are accessed …
[HTML][HTML] Gefitinib in non-small-cell lung cancer—an old lesson new re-visited
WCM Dempke - Translational Lung Cancer Research, 2013 - ncbi.nlm.nih.gov
Non-small cell lung cancer (NSCLC) accounts for approximately 80-85% of all cases of lung
cancer, and it is the most common cause of death in men and second only to breast cancer …
cancer, and it is the most common cause of death in men and second only to breast cancer …
[HTML][HTML] Biopsy testing in an inoperable, non-small cell lung cancer population—a retrospective, real-life study in Sweden
H Koyi, L Johansson, J From, S Nyrén - Journal of thoracic disease, 2015 - ncbi.nlm.nih.gov
Background Correct diagnosis and staging are required for optimal treatment choice in lung
cancer patients. This retrospective, patient medical records study investigated the clinical …
cancer patients. This retrospective, patient medical records study investigated the clinical …
[HTML][HTML] Los medicamentos de origen biotecnológico, el futuro comienza ahora
JE Machado-Alba - Anales de la Real Academia Nacional de …, 2014 - anales.ranf.com
Los medicamentos de origen biotecnol—gico pueden ser anticuerpos monoclonales o
molŽculas peque–as dise–adas para actuar sobre blancos terapŽuticos definidos. Se hizo …
molŽculas peque–as dise–adas para actuar sobre blancos terapŽuticos definidos. Se hizo …